Do not transfuse a stable neonate by hemoglobin/hematocrit alone. Decide using gestational age, postnatal age, respiratory or cardiovascular support, reticulocyte response, phlebotomy losses, growth, apnea/tachycardia, perfusion, and evidence of acute blood loss or hemolysis.
This chapter standardizes the NICU approach to anemia of prematurity, acute blood loss, hemolytic anemia, transfusion thresholds, PRBC administration, transfusion safety, and follow-up after hemolytic disease or significant transfusion exposure.
| Principle | Bedside Application |
|---|---|
| Treat the baby, not only the number | Use Hb/Hct with respiratory support, perfusion, oxygen need, apnea, tachycardia, growth, reticulocyte response, and acuity of blood loss. |
| Prevent anemia before treating it | Use delayed cord clamping when appropriate, reduce phlebotomy, cluster labs, use micro-sampling, optimize iron and nutrition, and avoid unnecessary testing. |
| Use restrictive thresholds when clinically safe | Large randomized trials (TOP, ETTNO) did not show improved death or neurodevelopmental outcomes with higher transfusion thresholds in extremely preterm infants. |
| Use the safest feasible product | Routine neonatal PRBCs should be leukoreduced and CMV-safe/negative; use irradiated products when indicated by local policy, IUT history, suspected immunodeficiency, family donor, or HLA-selected donor. |
| Document benefit | Record indication, consent, pre- and post-transfusion Hb/Hct, product type, volume, rate, monitoring, and whether the clinical problem improved. |
| Pattern | Key Bedside Clues |
|---|---|
| Acute blood loss / hypovolemia | Pallor, tachycardia, poor perfusion, hypotension, metabolic acidosis, oliguria, rising lactate, falling Hb/Hct. Examples: fetomaternal hemorrhage, subgaleal hemorrhage, pulmonary hemorrhage, surgical bleeding, placental abruption. |
| Anemia of prematurity | Progressive fall in Hb/Hct in a preterm infant due to low erythropoietin response, rapid growth, shorter RBC survival, illness, and repeated phlebotomy. Symptoms may include recurrent apnea, persistent tachycardia, poor growth, feeding fatigue, and increased respiratory support. |
| Hemolytic anemia | Early jaundice, positive DAT, maternal antibodies, high reticulocyte count, spherocytes or other smear findings, rapidly rising bilirubin, late anemia after Rh/ABO/minor-antigen disease or after intrauterine transfusion. |
| Underproduction / marrow suppression | Low or inappropriately normal reticulocyte response. Consider prematurity, inflammation, infection, maternal Kell antibodies, congenital infection, nutritional deficiency, or marrow failure syndrome. |
| Iatrogenic anemia | Frequent blood sampling in ELBW or critically ill infants. Prevent by minimizing sample volume, batching labs, point-of-care testing when safe, and avoiding routine non-actionable tests. |
Do not wait for a routine threshold if the infant has acute blood loss with hemodynamic compromise, shock physiology, worsening metabolic acidosis, or ongoing hemorrhage. Give emergency blood according to local massive hemorrhage policy and call neonatology, hematology/transfusion medicine, and blood bank early.
| Clinical Scenario | Recommended Assessment |
|---|---|
| Stable anemia of prematurity | CBC with Hb/Hct, reticulocyte count if it will change management, recent phlebotomy history, growth and nutrition review, respiratory-support trend, iron intake, and review for occult blood loss. |
| Acute blood loss or shock | CBC/Hb/Hct repeated as needed, blood gas/lactate, coagulation profile if bleeding is significant, glucose, calcium, type and screen/crossmatch, and focused search for hemorrhage source. |
| Suspected hemolysis | Maternal and infant ABO/Rh, DAT, antibody screen, bilirubin trend, reticulocyte count, smear, G6PD when appropriate, and consideration of hereditary spherocytosis/elliptocytosis or enzymopathy. |
| After IUT / exchange / IVIG or significant hemolytic disease | Plan discharge Hb, bilirubin, folate/iron/nutrition review, and outpatient Hb surveillance — late anemia may occur after discharge. |
| Before first transfusion | Confirm consent unless emergency, neonatal and maternal sample requirements, antibody status, product specifications, and whether a newborn screen or pre-transfusion blood spot is needed by local policy. |
Use as a bedside guide for clinically stable infants. Thresholds should be individualized for cyanotic heart disease, pulmonary hypertension, shock, active bleeding, severe hypoxemia, ECMO/cardiac surgery, exchange transfusion, or rapidly evolving illness.
| Clinical Category | Examples | Age 1–7 d | Age 8–14 d | Age >14 d |
|---|---|---|---|---|
| Severe illness | Mechanical ventilation; NIPPV/CPAP/HFNC >2 L/min with FiO₂ >0.40; hypotension; acute sepsis/NEC with inotropes or vasopressors. | Hct <33% (Hb ~11 g/dL) |
Hct <30% (Hb ~10 g/dL) |
Hct <27% (Hb ~9 g/dL) |
| Moderate illness | NIPPV/CPAP/HFNC >2 L/min with FiO₂ ≤0.40. | Hct <30% (Hb ~10 g/dL) |
Hct <30% (Hb ~10 g/dL) |
Hct <25% (Hb ~8.3 g/dL) |
| Mild illness with symptoms | No support or ≤2 L/min, but symptoms strongly attributable to anemia: poor growth despite calories, significant apnea, persistent tachycardia >24 hr. | Hct <30% (Hb ~10 g/dL) |
Hct <27% (Hb ~9 g/dL) |
Hct <23% (Hb ~7.7 g/dL) |
| Asymptomatic / growing | Clinically stable, no meaningful apnea/tachycardia/growth concern attributable to anemia. | Hct <30% (Hb ~10 g/dL) |
Hct <25% (Hb ~8.3 g/dL) |
Hct <21% (Hb ~7 g/dL) |
Thresholds are not "automatic orders." Reassess if the infant is improving, if symptoms have another explanation, if the sample may be diluted, or if the transfusion risk outweighs expected benefit. Conversely, transfuse earlier when oxygen delivery is clearly impaired or bleeding is ongoing.
| Item | Practical Standard |
|---|---|
| Routine PRBC product | Leukoreduced, CMV-safe or CMV-negative, ABO/Rh compatible, crossmatched according to maternal and neonatal antibody status, and irradiated when required by local policy. |
| Irradiated PRBCs — strong indications | Prior intrauterine transfusion; exchange or large-volume transfusion by policy; suspected/proven immunodeficiency; blood from first- or second-degree relative; HLA-selected donor; or local neonatal standard. |
| Emergency hemorrhage | Use immediately available emergency blood per local protocol — often group O RhD-negative PRBCs — while obtaining crossmatched blood as soon as feasible. |
| Multiple transfusions in ELBW / preterm infants | Use aliquots or satellite packs from a single donor when available to minimize cumulative donor exposure. |
| Crossmatch and antibody considerations | For the first transfusion, ensure neonatal and maternal samples are available if local policy requires; if maternal antibody screen is positive, repeat compatibility testing may be required for each subsequent transfusion. |
| Before transfusion checklist | Verify consent or emergency exception, indication, product specifications, patient identity, route, volume, rate, baseline temperature/HR/BP/SpO₂, glucose/calcium risk when relevant, and IV access. |
| Situation | Recommendation |
|---|---|
| Stable top-up transfusion | 15 mL/kg PRBC over 2–4 hours; use local maximum rate and monitoring policy. |
| Acute blood loss with hemodynamic compromise | 10 mL/kg can be given rapidly — often over ~30–60 minutes or per massive hemorrhage policy — then reassess perfusion, Hb/Hct, lactate, calcium, temperature, and ongoing bleeding. |
| Large correction in ELBW or high-risk infant | Avoid sudden volume overload. If 20 mL/kg is needed, consider splitting into 10 mL/kg aliquots separated by reassessment. |
| Severe anaemia where volume load is the problem | Consider an isovolemic transfusion — raising the haematocrit without circulatory overload. The technique mirrors an exchange transfusion, and the volume is calculated as for polycythaemia: Volume exchanged (mL) = [Hctdesired − Hctobserved] × weight (kg) × 80 mL/kg ÷ Hctpacked cells 80 mL/kg is the assumed circulating blood volume; the haematocrits are percentages and must be entered consistently. Entering the packed-cell haematocrit as a fraction rather than a percentage inflates the answer roughly a hundredfold — check the magnitude before drawing anything up. |
| Access | Use a peripheral venous catheter or UVC when appropriate. Avoid arterial lines/UACs and avoid long lines/PICCs for routine blood unless local vascular-access policy specifically permits. |
| Monitoring | Continuous cardiorespiratory and SpO₂ monitoring; record vitals before, during, and after transfusion. Watch for respiratory decompensation, fever, rash, hypotension, hemoglobinuria, hyperkalemia, hypocalcemia, hypoglycemia, and volume overload. |
| Furosemide | Do not use routinely. Consider only for specific risk of fluid overload, heart failure, significant PDA, chronic lung disease with fluid sensitivity, or edema — and document the reason. |
| Enteral feeds during transfusion | Evidence is insufficient for a universal rule. Continue or hold feeds according to unit policy and individual NEC risk; do not apply preterm high-risk practices to term infants without a reason. |
| Scenario | Action |
|---|---|
| Hemolytic disease / blood group incompatibility | Monitor bilirubin and Hb early; consult senior neonatology if DAT positive, prior IUT, rapidly rising bilirubin, or anemia. Before discharge, check Hb/bilirubin and arrange follow-up for late anemia when hemolysis was clinically important. |
| Late anemia after IUT, exchange transfusion, or IVIG | Arrange outpatient Hb checks — often every 1–2 weeks initially until stable; transfuse if symptomatic or if Hb is very low according to local policy. |
| Fetomaternal hemorrhage | Consider if severe pallor, shock, hydrops, low reticulocyte response early, abnormal placental history, or unexplained fetal distress. Send maternal Kleihauer-Betke/flow cytometry where available. |
| Subgaleal hemorrhage | Treat as concealed hemorrhage: serial head circumference measurements, shock monitoring, Hb/Hct trend, coagulation assessment, early blood bank involvement, and jaundice surveillance. |
| Cyanotic CHD or pulmonary hypertension | Thresholds may be higher because oxygen content is Hb-dependent; individualize with cardiology/neonatology and avoid hyperviscosity. |
| NEC / TANEC concern | Do not assume transfusion alone causes NEC. Severe anemia itself may be a confounder or contributor. Feed management during transfusion should follow local policy and individual risk assessment. Baylor Ed. 33: the TANEC evidence is limited, mostly retrospective, conflicting, and drawn from infants fed non-human milk. Recent meta-analyses and trials point to the severity of anemia rather than the transfusion itself. Its approach is to prevent severe anemia by following transfusion thresholds in infants <1500 g, and not to hold feeds routinely for a red-cell transfusion — holding one feed around the transfusion may be considered when anemia is severe or there is feeding intolerance. |
| Strategy | Bedside Implementation |
|---|---|
| Delayed cord clamping | Use when clinically appropriate as part of anemia prevention and transfusion reduction strategy. Do not delay urgent resuscitation when immediate stabilization is required. |
| Phlebotomy stewardship | Cluster labs, avoid routine daily CBCs without an action plan, use microtubes, reduce discarded line volumes, and review cumulative blood loss in ELBW infants. |
| Iron | Start enteral iron when the infant is tolerating adequate enteral feeds and local nutrition criteria are met; monitor for adequate total iron intake in human-milk-fed preterm infants. |
| Nutrition | Optimize protein, calories, vitamins, and minerals — anemia will not correct without adequate growth substrate. |
| Erythropoietin / darbepoetin | Do not use routinely solely to avoid transfusion; benefits are limited once donor exposure has occurred and evidence does not support routine practice. Consider only by institutional protocol or specialist plan. |
| Folate | Consider in infants with hemolytic disease according to local practice, especially if ongoing reticulocytosis or late anemia follow-up is planned. |
| Step | Question | Action |
|---|---|---|
| Step 1 | Is the baby actively bleeding, in shock, acidotic, or rapidly deteriorating? | Yes: activate hemorrhage/shock pathway and transfuse emergently. No: continue to Step 2. |
| Step 2 | Confirm anemia and context. | Review Hb/Hct trend, reticulocytes if useful, respiratory/cardiovascular support, oxygen need, growth, apnea/tachycardia, phlebotomy burden, and hemolysis risk. |
| Step 3 | Classify severity of illness. | Use the transfusion-threshold table (Section 5) only after clinical classification and sample validity are confirmed. |
| Step 4 | Prepare safest feasible product. | Consent, type/screen, maternal antibody status, neonatal ID, CMV-safe/leukoreduced/irradiated status, route, volume, rate, and monitoring. |
| Step 5 | Give transfusion and reassess. | Document response: perfusion, oxygen/ventilator need, apnea/tachycardia, lactate, post-transfusion Hb/Hct when indicated, and adverse effects. |
| Step 6 | Prevent recurrence. | Reduce phlebotomy, optimize iron/nutrition, plan late anemia follow-up, and avoid repeated transfusion without reassessing the cause. |
| Source | How It Informed This Chapter |
|---|---|
| Baylor 2025–2026 | Uses illness-severity and postnatal-age Hct thresholds; emphasizes TOP/ETTNO evidence, 15 mL/kg PRBC over 2–4 hr, minimizing donor exposure, and no routine EPO. |
| West Midlands 2025–2028 | Uses Hb thresholds by respiratory support and age; adds detailed crossmatch, CMV-negative, irradiated blood, iron timing, feed-withholding uncertainty, and transfusion monitoring. |
| Belize 2018–2021 | Provides practical blood-component principles, emergency transfusion steps, volume formulas, donor-exposure reduction, product preparation, transfusion reactions, and documentation standards. |
| Updated evidence | TOP and ETTNO support restrictive thresholds in extremely preterm infants; the 2024 Neonatal Transfusion Network guideline (Deschmann et al.) provides consensus threshold recommendations for very preterm neonates. |
This is an educational guideline synthesis. For patient care, use local transfusion-service policies, blood product availability, neonatal hematology consultation, and institutional thresholds.